Stockscreener 앱 받기
1.06
1.92%
0.02
시장 영업 전:
1.04
-0.02
-1.89%
Maxcyte Inc 주식(MXCT)의 최신 뉴스
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Q1 earnings call highlights - MSN
What MaxCyte (MXCT)'s -4.59% Decline Means for Investors 2026-05-15Stock Idea Sharing Hub - newser.com
MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsExpert Entry Points - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake - TradingView
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares - Stock Titan
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus - Sahm
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - Sahm
MSN Money - MSN
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall - Stock Titan
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
BTIG Maintains MaxCyte(MXCT.US) With Hold Rating - Moomoo
MaxCyte posts $4.8M loss, still lines up $10M stock buyback - Stock Titan
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED) - Benzinga
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript - Insider Monkey
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - Insider Monkey
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
MaxCyte Q1 Earnings Call Highlights - sharewise.com
MaxCyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue By Investing.com - Investing.com South Africa
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue - Investing.com Nigeria
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MaxCyte Reports Q1 2026 Results, Launches Share Buyback - TipRanks
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - The Manila Times
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - Moomoo
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... By GuruFocus - Investing.com Canada
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
BTIG Downgrades MaxCyte (MXCT) - MSN
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 - The Manila Times
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
SEC Form DEFA14A filed by MaxCyte Inc. - Quantisnow
[ARS] MAXCYTE, INC. SEC Filing - Stock Titan
Directors and auditor on ballot at MaxCyte (NASDAQ: MXCT) 2026 meeting - Stock Titan
MaxCyte schedules May 12 earnings release, 4:30 p.m. call - Stock Titan
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27Crowd Consensus Signals - newser.com
MaxCyte announces 34% workforce reduction to cut costs - MSN
1.72%
자본화:
|
볼륨(24시간):